ExodusPoint Capital Management LP Grows Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

ExodusPoint Capital Management LP lifted its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 965.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 127,161 shares of the company’s stock after acquiring an additional 115,223 shares during the period. ExodusPoint Capital Management LP owned approximately 0.18% of Kiniksa Pharmaceuticals worth $2,515,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in KNSA. Quarry LP acquired a new stake in Kiniksa Pharmaceuticals in the 3rd quarter valued at $50,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Kiniksa Pharmaceuticals in the third quarter worth about $189,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter worth about $158,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Kiniksa Pharmaceuticals by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock valued at $174,000 after buying an additional 1,004 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its holdings in shares of Kiniksa Pharmaceuticals by 7.1% during the 4th quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company’s stock valued at $215,000 after buying an additional 719 shares during the period. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on KNSA shares. Wedbush restated an “outperform” rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Citigroup began coverage on shares of Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a “buy” rating and a $40.00 price target for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals presently has an average rating of “Buy” and an average price target of $37.17.

Insider Transactions at Kiniksa Pharmaceuticals

In related news, COO Eben Tessari sold 14,000 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $18.24, for a total transaction of $255,360.00. Following the sale, the chief operating officer now directly owns 88,975 shares of the company’s stock, valued at approximately $1,622,904. This represents a 13.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Michael R. Megna sold 9,051 shares of Kiniksa Pharmaceuticals stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total transaction of $203,194.95. Following the completion of the transaction, the chief accounting officer now directly owns 26,528 shares of the company’s stock, valued at approximately $595,553.60. This represents a 25.44 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 93,766 shares of company stock valued at $2,011,735. Insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Stock Down 0.4 %

Shares of KNSA opened at $20.28 on Tuesday. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of -144.85 and a beta of 0.31. The business’s 50 day moving average is $20.99 and its two-hundred day moving average is $21.80. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $16.56 and a 52-week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The company had revenue of $122.50 million during the quarter, compared to analyst estimates of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company’s revenue was up 46.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.35 earnings per share. On average, equities analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.